NeuroRx Presents Phase 2 Efficacy & Safety Data for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression | Small Molecules | News Channels - PipelineReview.com

Submitted by Anonymous (not verified) on Fri, 12/14/2018 - 20:03

NeuroRx Presents Phase 2 Efficacy & Safety Data for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression | Small Molecules | News Channels  PipelineReview.comNeuroRx Presents Phase 2 Efficacy & Safety Data for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression.